Gabapentin produces dose-dependent antinociception in the orofacial formalin test in the rat
Gabapentin produces dose-dependent antinociception in the orofacial formalin test in the rat
复制标题
DOI：
10.1053/rapm.2002.30740
复制
发表时间：
2002-05-01
影响因子：
5.1
通讯作者：
Dougherty, PM
中科院分区：
文献类型：
--
作者：
Grabow, TS;Dougherty, PM
背景和目的：高神经轴向药物输注已被提倡用于治疗人类顽固性头面部疼痛。目前，平行动物模型还没有特征来支持这一方法。我们将公认的颅源性疼痛动物模型与一种新的颈髓给药技术相结合，以确定加巴喷丁的抗伤害感受潜力。加巴喷丁之所以被选择，是因为有报道称它对一系列复杂的颅痛综合征有疗效。方法：雄性Wistar大鼠在鞘内植入导管，导管通过腰椎导管头超前，终止于高位颈髓(C1-C4)。用口面部福尔马林试验评价抗伤害性。鞘内注射赋形剂或加巴喷丁(3、10、30、100µg)，10分钟后在振动垫内注入2.5%福尔马林溶液。结果：鞘内注射加巴喷丁(10、30、100µg)可剂量依赖性地降低福尔马林引起的第二时相行为反应(P
Background and objectives: High neuraxial drug infusion has been advocated for the treatment of intractable cranial and facial pain in humans. Currently, parallel animal models have not been characterized to support this methodology. We combined an accepted animal model of pain of cranial origin with a novel technique of cervico-medullary drug delivery to determine the antinociceptive potential of gabapentin. Gabapentin was chosen because of its reported efficacy in a wide array of complex cranial pain syndromes.Methods: Male Wistar rats were implanted with intrathecal catheters that were advanced cephalad through a lumbar guide cannula to terminate in the high cervical spinal cord (C1-C4). Antinociception was assessed by the orofacial formalin test. Vehicle or gabapentin (3, 10, 30, 100 mug) was injected intrathecally followed 10 minutes later by injection of 2.5 % formalin solution into the vibrissal pad. Motor assessment was evaluated in a separate group of animals.Results: Intrathecal gabapentin (10, 30, 100 mug) produced a dose-dependent decrease in the second phase of the behavioral response to formalin (P